5 results
A decrease in the incidence of central line-associated bloodstream infections in the investigational study group, compared to the control group.
At least 90% of the subjects, with 95% confidence, will tolerate the test formula.
The test product supports normal physical growth in healthy term infants
Primary Objectives: -To evaluate if the treatment of Low Risk HB can be reduced (Group B1) -To compare different induction treatment regimens for Intermediate risk HB (Group C) -To compare different post induction treatment regimens for…
To analyze the number of patients with (germline/somatic) actionable molecular aberrations in patients with relapsed/refractory pediatric tumors for whom no standard treatment or study protocol is available.